Delhi, January 2: Union Health and Family Welfare Minister JP Nadda on Friday released the Indian Pharmacopoeia 2026 (IP 2026) - the 10th edition of India’s official book of drug standards here marking a significant milestone in India’s ongoing efforts to strengthen the quality, safety, and efficacy of medicines.
Releasing the new edition, Nadda said, “Indian Pharmacopoeia serves as the official book of standards for drugs in the country and is a cornerstone of India’s regulatory framework for pharmaceuticals. The 10th edition reflects scientific advancements, global best practices, and India’s growing leadership in pharmaceutical manufacturing and regulation.”
He also highlighted that Indian Pharmacopoeia 2026 incorporated 121 new monographs, increasing the total number of monographs to 3,340.
Highlighting significant regulatory advancements, the Minister underscored the first-time inclusion of 20 blood component monographs pertaining to transfusion medicine in the Indian Pharmacopoeia 2026, in accordance with the provisions of the Drugs and Cosmetics (Second Amendment) Rules, 2020.
Referring to pharmacovigilance, Union Health Minister stated that, “In recent years, the Indian Pharmacopoeia standards have also gained international acceptance as it has become a focused agenda under the health diplomacy of the Government of India. He also noted that, Indian Pharmacopoeia is now recognised in 19 countries of the global south.
Nadda also highlighted the remarkable progress of the Pharmacovigilance Programme of India (PvPI) under the Indian Pharmacopoeia Commission (IPC).
“India, which was ranked 123rd globally in terms of contributions to the World Health Organization’s pharmacovigilance database during 2009-2014, has now risen to 8th position worldwide in 2025,” said Nadda.
“Under the visionary leadership of Prime Minister Narendra Modi, the Government of India has consistently worked towards strengthening healthcare systems and regulatory institutions. The Indian Pharmacopoeia 2026 is a reflection of this sustained effort and the Government’s unwavering focus on quality, transparency, and public welfare,” said Nadda.
The Indian Pharmacopoeia (IP) is published by the Indian Pharmacopoeia Commission (IPC) on behalf of Ministry of Health & Family Welfare, Government of India to fulfil the requirements of the Drugs and Cosmetics Act 1940.
IP prescribes the official standards for drugs produced and/or marketed in India and thus contributes in the control and assurance of the quality of the medicines.
